ADHD

FDA Rejects ADHD Drug NDA Citing Need for More Data

By August 31, 2018

The FDA stated that the dasotraline NDA cannot be approved in its current form and is requiring additional data to further assess the efficacy and tolerability of the drug.

ADHD Medications Compared for Efficacy, Tolerability in Children and Adults

By August 13, 2018

The 7 treatments included in the study were amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate, and modafinil.

Jornay PM Approved for the Treatment of ADHD

By August 09, 2018

Jornay PM utilizes the proprietary Delexis drug delivery platform which consists of 2 functional film coatings: the first layer delays the initial drug release for up to 10 hours and the second layer helps control the release rate of the active ingredient throughout the day.

Off-Label Prescribing Common With Certain Psychiatric Medications

By July 26, 2018

Using data from the 2012 and 2013 National Ambulatory Medical Care Surveys, researchers looked at all adult outpatient visits to psychiatric practices for chronic care management in which ≥1 psychiatric medication was prescribed.

High Frequency of Digital Media Use May Lead to Development of ADHD Symptoms

July 18, 2018

There was a correlation for high-frequency engagement in each additional digital media activity at baseline with a significantly increased odds of having ADHD symptoms across follow-up (odds ratio, 1.11).

NDA for ADHD Med That Is Dosed at Night Resubmitted to FDA

By July 12, 2018

HLD200 is a delayed-release and extended-release formulation of methylphenidate.

Early Preterm Birth Linked to Increased ADHD Symptoms

June 26, 2018

The correlation between gestational age at birth and symptoms of ADHD in preschool and school-age children was compared after adjustment for unmeasured genetic and environmental risk factors.

Exposure to Maternal HTN May Up Risk of ASD, ADHD in Child

June 13, 2018

The researchers found that 11 of 20 studies that reported estimates for ASD (777,518 participants) found higher odds with HDP (adjusted odds ratio [aOR], 1.35) in pooled analysis. For the 6 studies reporting adjusted estimates of ADHD (1,395,605 participants), the pooled adjusted OR was 1.29.

Increase in Pediatric ADHD Meds Exposures from 2000 to 2011

May 23, 2018

Intentional meds exposure most often reported among teens, accounting for half of teen exposure

Prescription Med Use in Children Down Overall From 1999 to 2014

May 16, 2018

Asthma medications, antibiotics, attention-deficit/hyperactivity disorder (ADHD) medications, topical agents, and antihistamines were the most commonly used medication classes in 2011 to 2014.

ADHD Frequently Co-Occurs with Autism Spectrum Disorder

April 05, 2018

The researchers found that 45.3% of the 3,319 children included in the analysis had ADHD. Comorbid ADHD increased with age (P<0.001) and was associated with increased ASD severity.

ADHD Incidence Increases Significantly Following Childhood TBI

March 20, 2018

The researchers found that 25.7% of the 187 children met the definition of SADHD. Compared with the OI group, severe TBI correlated with SADHD (hazard ratio [HR], 3.62; 95% confidence interval [CI], 1.59 to 8.26).

Adzenys ER Oral Suspension Launched for ADHD

By February 26, 2018

The once-daily medication uses the same modified-release drug delivery technology seen in Adzenys XR-ODT (amphetamine) Extended-Release Orally Disintegrating Tablets.

Is There Any Link Between Ultrasound Exposure and Autism?

February 14, 2018

The ASD group had a shorter duration of ultrasound exposure than the typical development group during the first (290.4 versus 406.4 seconds) and second (1,687.6 versus 2,011 seconds) trimesters. Greater mean depth of ultrasonographic penetration was seen in the ASD group versus the developmental delay group in the first trimester (12.5 versus 11.6 cm).

Are Psychiatric Drugs Being Overprescribed in Children and Adolescents?

By January 30, 2018

"Our results show that, at a population level, prescriptions of stimulants and antidepressant medications for children and adolescents do not appear to be prescribed at rates higher than the known rates for psychiatric conditions they are designed to treat," said the study's lead author, Dr. Ryan Sultan.

AHRQ: Update on ADHD Diagnosis and Treatment

By January 26, 2018

Evidence was contributed from 103 articles describing 90 unique studies.

Shortage of Two ADHD Medications Due to Manufacturing Delays

By January 22, 2018

Quillivant XR and Quillichew ER are currently in short supply.

ADHD Medication Use Increasing Among Reproductive-Aged Women

By January 18, 2018

ADHD medication prescriptions are increasingly common among privately insured, reproductive-aged women.

Psychostimulant Use Linked to Preeclampsia, Preterm Birth

November 15, 2017

Small increased relative risk of preeclampsia, preterm birth; absolute risk increases are small

Acetaminophen Use During Pregnancy Linked to Offspring ADHD

By October 30, 2017

Results showed that after adjusting for maternal use of acetaminophen pre-pregnancy, familial risk and indications of acetaminophen use, the hazard ratio (HR) of ADHD with ≥29 days of acetaminophen use was 2.20 (95% CI; 1.50-3.24).

Prevalence of Nonmedical Amphetamine Use May Be Underreported

October 27, 2017

Researchers analyzed prevalence and correlates of discordant responses among past-year Adderall users, defined as reporting past-year nonmedical Adderall use but not past-year nonmedical amphetamine use.

Nationwide Availability of Cotempla XR-ODT for ADHD Announced

By October 02, 2017

Cotempla XR-ODT is a Schedule II controlled substance and is supplied as 8.6mg, 17.3mg, and 25.9mg strength orally-disintegrating tablets in cartons containing 5 blister cards of 6 tablets each.

Adzenys ER Approved for the Treatment of ADHD

By September 18, 2017

Adzenys ER is a once-daily extended-release liquid that does not need to be reconstituted or refrigerated.

Over 1 Million ADHD Patches Recalled Due to Liner Defect

By September 12, 2017

This error can make it difficult for patients and caregivers to remove the liners from the Daytrana patches.

Cotempla XR-ODT Available for Pediatric ADHD

By September 08, 2017

Cotempla XR-ODT contains methylphenidate, a central nervous system (CNS) stimulant.

FDA to Review Novel ADHD Treatment Dasotraline

By August 31, 2017

Two year-long studies assessing safety of dasotraline in children, adolescent and adult ADHD patients found the treatment to be generally well tolerated.

Neuroanatomic Abnormalities Identified in Those at High Risk for Autism

August 09, 2017

"In two genetically related cohorts at high risk for autism spectrum disorder, reciprocal neuroanatomic abnormalities were found and determined to be associated with cognitive and behavioral impairments," the authors write.

Treatment Shows Efficacy in Binge Eating Disorder

August 04, 2017

In both studies, more participants on LDX versus placebo were categorized as improved on the Clinical Global Impressions-Improvement starting at week one.

ADHD Med Adherence and Long-Term Substance Abuse Risk Examined

July 25, 2017

Patrick Quinn, PhD, of Indiana University Bloomington, and colleagues looked at data from 2,993,887 Americans with ADHD.

Maternal Antidepressant Use May Contribute to Offspring Autism

July 21, 2017

"Importantly, the absolute risk of autism was small, and, hypothetically, if no pregnant women took antidepressants, the number of cases that could potentially be prevented would be small," wrote the authors of the study.